Avience Biomedicals Ltd (NSE SME)

Avience Biomedicals Ltd (NSE SME)

NSE - SMEClosed
Min. Investment
₹1,24,800
/ 600 Shares
Check Allotment Status
Issue Price
196-208
Subscription
-
Issue Size
30.24
Lot Size
600
Open
Jun 18, 2026
Close
Jun 22, 2026
Allotment
Jun 23, 2026
Listing
Jun 25, 2026

1. Avience Biomedicals Ltd (NSE SME) IPO Details

Avience Biomedicals Ltd IPO is a book-built issue of ₹30.24 crores. The issue consists entirely of a fresh issue of 14.54 lakh shares (specifically 14,53,800 equity shares), with no offer-for-sale (OFS) component.

The bidding for the IPO starts this Thursday, Jun 18, 2026, and ends on Jun 22, 2026. The allotment is expected to be finalized on Jun 23, 2026. The company will list on the NSE SME platform, with a tentative listing date fixed as Jun 25, 2026.

The price band is set at ₹196–₹208 per share. The lot size for an application is 600 shares, but the minimum application for retail investors is 2 lots (1,200 shares). The minimum amount of investment required by a retail investor is ₹2,49,600.

Grey Market Premium

Estimated listing gains (Live)

+145 (69.7%)Per Share
EST. GAINS
Updated real-time from market sources

Financial Summary

Period Ended31 Jan 202631 Mar 202531 Mar 2024
Assets66.0756.5234.65
Total Income41.9445.9724.37
Profit After Tax5.747.232.14
EBITDA10.3411.414.08
NET Worth28.5222.786.21
Reserves and Surplus24.4918.752.93
Total Borrowing26.7322.1615.13

IPO Details

IPO Date18 to 22 Jun, 2026
Listing DateThu, Jun 25, 2026 T
Face Value₹ 10 per share
Price Band₹196 to ₹208
Lot Size600 Shares
Sale TypeFresh capital only
Issue TypeBookbuilding IPO
Listing AtNSE SME
Total Issue Size14,53,800 shares (agg. up to ₹ 30 Cr)
Reserved for Market Maker82,200 shares (agg. up to ₹ 2 Cr) Asnani Stock Broker Pvt.Ltd.
Fresh Issue (Ex Market Maker)13,71,600 shares (agg. up to ₹ 29 Cr)
Net Offered to Public13,71,600 shares (agg. up to ₹ 29 Cr)
Share Holding Pre Issue40,31,256 shares
Share Holding Post Issue54,85,056 shares

Issue Reservation

Investor CategoryShares Offered% of Net Issue% of Total Issue
QIB Shares Offered6,83,40049.83%47.01%
− Anchor Investor Shares Offered4,09,800-28.19%
− QIB (Ex. Anchor) Shares Offered2,73,600-18.82%
NII (HNI) Shares Offered2,07,00015.09%14.24%
− bNII > ₹10L1,38,000-9.49%
− sNII < ₹10L69,000-4.75%
Retail Shares Offered4,81,20035.08%33.10%
Market Maker Shares Offered82,200-5.65%
Total Shares Offered14,53,800100.00%100.00%

IPO Lot Size

ApplicationLotsSharesAmount
Individual investors (IND) (Min)21,200₹2,49,600
Individual investors (IND) (Max)21,200₹2,49,600
S-HNI (Min)31,800₹3,74,400
S-HNI (Max)84,800₹9,98,400
B-HNI (Min)95,400₹11,23,200

Recently Listed IPOs in Pharmaceuticals & Biotechnology

CompanyIssue TypeIssue SizeIssue PriceListing Day CloseListing Gain/Loss %LTP
Anthem Biosciences Ltd.Mainboard₹3,395.00 Cr₹570₹730.35+28.13%₹773.45 ( -1.97% )

IPO Objects of the Issue

#Issue ObjectsEst Amt (₹ Cr.)
1Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh15.96
2Funding the working capital requirements of the Company8.25
3General Corporate Purposes
Total24.21

Key Performance Indicator (KPI)

KPIJan 31, 2026Mar 31, 2025
ROE22.38%50.14%
ROCE16.99%24.84%
Debt/Equity0.940.97
RoNW22.38%49.89%
PAT Margin-15.86%
EBITDA Margin24.70%25.22%
Price to Book Value2.943.68

Pre/Post IPO Valuation

ParameterPre IPOPost IPO
EPS (₹)17.9412.56
P/E (x)11.5916.56
Promoter Holding87.89%64.59%
Market Cap₹ 114.09 Cr.-

Avience Biomedicals IPO Recommendations

Review BySubscribeMay ApplyNeutralAvoid
Brokers1000
Members0000

2. About Avience Biomedicals Ltd (NSE SME)

Avience Biomedicals Limited is an emerging enterprise operating within the pharmaceuticals and biotechnology sector. The company focuses on expanding its presence in medical solutions, manufacturing high-grade healthcare inputs, and catering to institutional healthcare networks.

Business Verticals

  • Medical Device & Pharmaceutical Manufacturing: Setting up state-of-the-art production environments to engineer critical medical tools and formulations.

  • B2B Healthcare Supply Chain: Delivering medical-grade products to clinical networks, institutional buyers, and pharmaceutical partners.

Track Record

  • Revenue Performance: Total operational income stood at ₹24.37 Cr in FY24, scaled up to ₹45.97 Cr in FY25, and reported a steady ₹41.94 Cr for the 10-month period ending January 31, 2026.

  • Profitability: Net profit (PAT) registered strong momentum, growing from ₹2.14 Cr in FY24 to ₹7.23 Cr in FY25, and posting ₹5.74 Cr for the period ending January 2026.

  • Anchor Interest: The company has set aside an institutional reservation of 4.09,800 shares dedicated entirely to Anchor Investors to back its baseline capital需求.

Avience Biomedicals Ltd IPO GMP

As of June 17, 2026, the Grey Market Premium (GMP) is trading around ₹75.

Note: Reflecting a robust premium of ~36.1% right before its public opening window, the grey market trends indicate an estimated initial listing price around ₹283 against the upper issue price cap of ₹208.

Avience Biomedicals Ltd IPO Allotment Status

The allotment is scheduled to be finalized on June 23, 2026.

Check Avience Biomedicals Allotment Status

To check your status online, visit the official exchange interfaces or monitor the updates via the designated tracking links.

You can verify your status via:

  • NSE official portal

  • Using your PAN number, Application ID, or DP ID/Client ID

Strengths

  • Attractive Operational Margins: Displays solid financial parameters with an EBITDA margin of 24.70% as of January 2026.

  • Strong Early Return Ratios: Showcased exceptional capital productivity with a Return on Equity (ROE) of 50.14% and a Return on Capital Employed (ROCE) of 24.84% in FY25.

  • Dedicated Enterprise Expansion: The upcoming facility layout signals a massive move into highly regulated medical parks, ensuring structural long-term growth.

Weaknesses

  • Leverage Positioning: Total borrowings have increased over recent cycles to ₹26.73 Cr as of January 2026, maintaining a debt-to-equity ratio of 0.94x.

  • Project Execution Timeline: Forward profit margins rely closely on the timely setup and seamless commercialization of the upcoming Gautam Buddha Nagar manufacturing plant.

How the Company Will Use IPO Money

The fresh issue proceeds (₹24.21 Cr net of core issue expenses) will be utilized for:

  • Capital Expenditure: Part financing the setup of a brand new medical devices manufacturing unit inside the specialized Medical Device Park (YEIDA) at Gautam Buddha Nagar, Uttar Pradesh (₹15.96 Cr).

  • Working Capital: Sourcing raw materials and managing day-to-day capital pipelines (₹8.25 Cr).

  • General Corporate Purposes: General corporate growth, brand promotion, and meeting listing-related administrative expenses.

Lead Manager & Registrar

  • Market Maker: Asnani Stock Broker Private Limited

  • Registrar Information: Allotment accounts and transactional database systems are systematically managed through the designated regulatory partners.

D
Founder | India IPO Updates

DIPAK DANGODARA

I am the founder of India IPO Updates, a platform dedicated to tracking the Indian IPO market since 2024. With a background in digital research and data analysis, I built this platform to simplify IPO tracking covering issue details, live Grey Market Premium (GMP), subscription status, and allotment updates sourced from public exchange data and verified market sources.

I am not an SEBI-registered investment advisor. All GMP and market data shared here is for informational purposes only and should not be considered investment advice. Investors are advised to consult a registered financial advisor before making investment decisions.